Horizon Pharma PLC (HZNP) Expected to Post Earnings of $0.53 Per Share
Equities analysts expect that Horizon Pharma PLC (NASDAQ:HZNP) will post earnings of $0.53 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Horizon Pharma’s earnings, with the lowest EPS estimate coming in at $0.48 and the highest estimate coming in at $0.55. Horizon Pharma reported earnings of $0.29 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 82.8%. The firm is expected to report its next earnings results on Wednesday, February 27th.
On average, analysts expect that Horizon Pharma will report full year earnings of $1.69 per share for the current fiscal year, with EPS estimates ranging from $1.60 to $1.72. For the next financial year, analysts expect that the company will post earnings of $1.83 per share, with EPS estimates ranging from $1.56 to $2.13. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.50 by $0.15. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The firm had revenue of $325.30 million during the quarter, compared to analysts’ expectations of $311.84 million. During the same quarter last year, the firm earned $0.26 earnings per share. The business’s revenue for the quarter was up 19.8% on a year-over-year basis.
In other Horizon Pharma news, Chairman Timothy P. Walbert sold 408,347 shares of the firm’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the completion of the sale, the chairman now owns 650,404 shares of the company’s stock, valued at $14,009,702.16. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.90% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HZNP. Scopia Capital Management LP boosted its position in shares of Horizon Pharma by 23.9% during the third quarter. Scopia Capital Management LP now owns 14,762,354 shares of the biopharmaceutical company’s stock worth $289,047,000 after buying an additional 2,850,064 shares during the period. Eagle Asset Management Inc. purchased a new position in shares of Horizon Pharma during the second quarter worth $39,795,000. Carillon Tower Advisers Inc. purchased a new position in shares of Horizon Pharma during the second quarter worth $29,905,000. Renaissance Technologies LLC boosted its position in shares of Horizon Pharma by 51.1% during the second quarter. Renaissance Technologies LLC now owns 5,014,300 shares of the biopharmaceutical company’s stock worth $83,037,000 after buying an additional 1,695,700 shares during the period. Finally, Jennison Associates LLC purchased a new position in shares of Horizon Pharma during the third quarter worth $27,670,000. Institutional investors and hedge funds own 88.64% of the company’s stock.
NASDAQ:HZNP opened at $20.90 on Thursday. Horizon Pharma has a one year low of $12.55 and a one year high of $23.38. The company has a quick ratio of 1.86, a current ratio of 1.94 and a debt-to-equity ratio of 2.06. The company has a market capitalization of $3.72 billion, a P/E ratio of 17.71, a P/E/G ratio of 1.47 and a beta of 1.29.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Featured Article: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.